US FDA grants priority review status to Johnson & Johnson’s nipocalimab BLA to treat generalized myasthenia gravis: Spring House, Pennsylvania Saturday, January 11, 2025, 12:00 ...
Patients with presbyopia experienced improvements in near vision after treatment with Brimochol PF in a second phase 3 ...
The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with ...
Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...
Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like ...
Pharmaceuticals and vector-control programmes have greatly diminished the once-widespread disease, but sustained effort will ...
Bio-Thera Solutions Inc. announced that it has partnered with Tabuk Pharmaceutical Manufacturing Company to commercialize BAT2206, ...
Among the health policy novelties of 2025, a new tool developed by the European Medicines Agency (EMA) is set to harmonise ...
GlobalData on MSN2d
EMA gives OMPD to Actuate’s pancreatic cancer therapyActuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback